PHARMACEUTICAL COMPOSITION, COMPRISING INHIBITORY PEPTIDE AGAINST FAS SIGNALING, FOR PREVENTION OR TREATMENT OF OBESITY, FATTY LIVER, OR STEATOHEPATITIS

PHARMACEUTICAL COMPOSITION, COMPRISING INHIBITORY PEPTIDE AGAINST FAS SIGNALING, FOR PREVENTION OR TREATMENT OF OBESITY, FATTY LIVER, OR STEATOHEPATITIS

The present invention relates to a pharmaceutical composition comprising an inhibitory peptide against Fas signaling as an active ingredient for prevention or treatment of obesity, fatty liver, or steatohepatitis. Binding specifically to Fas, which is extensively expressed in the liver and adipose t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ULLAH, Irfan, LEE, Sang-Kyung, LIM, Jae Yeoung, BAE, Su Min, CHUNG, Kunho
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator ULLAH, Irfan
LEE, Sang-Kyung
LIM, Jae Yeoung
BAE, Su Min
CHUNG, Kunho
description The present invention relates to a pharmaceutical composition comprising an inhibitory peptide against Fas signaling as an active ingredient for prevention or treatment of obesity, fatty liver, or steatohepatitis. Binding specifically to Fas, which is extensively expressed in the liver and adipose tissues in an obese state, the inhibitory peptide against Fas signaling exhibits high delivery rates to inflammatory regions caused by obesity and directly inhibits the Fas signaling, which is a main inflammation signaling pathway, to inhibit an inflammatory response. Therefore, the peptide can be advantageously used for alleviating or treating obesity, fatty liver, or steatohepatitis.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2022088115A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2022088115A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2022088115A13</originalsourceid><addsrcrecordid>eNqNzcEKgkAQxnEvHaJ6h4GuBmoEXkcbdUB3l91R8CQR2ykqsIfpcduiB-g0_OHHN8voZRq0HZbUC5fYQqk7ox0LaxV_w7JjVQOrhgsWbUcwZISPBFgjKydQoQPHtcI2wBgqbcFYGkh9RiCUWELpQoOuQBcU5sfgUGSElgey8Uc5CUo3ZFDCe7eOFpfTdfab311F24qkbHb-cZ_8_Did_c0_p95lSZYleZ6mB0z3_6k3zzBEOA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PHARMACEUTICAL COMPOSITION, COMPRISING INHIBITORY PEPTIDE AGAINST FAS SIGNALING, FOR PREVENTION OR TREATMENT OF OBESITY, FATTY LIVER, OR STEATOHEPATITIS</title><source>esp@cenet</source><creator>ULLAH, Irfan ; LEE, Sang-Kyung ; LIM, Jae Yeoung ; BAE, Su Min ; CHUNG, Kunho</creator><creatorcontrib>ULLAH, Irfan ; LEE, Sang-Kyung ; LIM, Jae Yeoung ; BAE, Su Min ; CHUNG, Kunho</creatorcontrib><description>The present invention relates to a pharmaceutical composition comprising an inhibitory peptide against Fas signaling as an active ingredient for prevention or treatment of obesity, fatty liver, or steatohepatitis. Binding specifically to Fas, which is extensively expressed in the liver and adipose tissues in an obese state, the inhibitory peptide against Fas signaling exhibits high delivery rates to inflammatory regions caused by obesity and directly inhibits the Fas signaling, which is a main inflammation signaling pathway, to inhibit an inflammatory response. Therefore, the peptide can be advantageously used for alleviating or treating obesity, fatty liver, or steatohepatitis.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220324&amp;DB=EPODOC&amp;CC=US&amp;NR=2022088115A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76517</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220324&amp;DB=EPODOC&amp;CC=US&amp;NR=2022088115A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ULLAH, Irfan</creatorcontrib><creatorcontrib>LEE, Sang-Kyung</creatorcontrib><creatorcontrib>LIM, Jae Yeoung</creatorcontrib><creatorcontrib>BAE, Su Min</creatorcontrib><creatorcontrib>CHUNG, Kunho</creatorcontrib><title>PHARMACEUTICAL COMPOSITION, COMPRISING INHIBITORY PEPTIDE AGAINST FAS SIGNALING, FOR PREVENTION OR TREATMENT OF OBESITY, FATTY LIVER, OR STEATOHEPATITIS</title><description>The present invention relates to a pharmaceutical composition comprising an inhibitory peptide against Fas signaling as an active ingredient for prevention or treatment of obesity, fatty liver, or steatohepatitis. Binding specifically to Fas, which is extensively expressed in the liver and adipose tissues in an obese state, the inhibitory peptide against Fas signaling exhibits high delivery rates to inflammatory regions caused by obesity and directly inhibits the Fas signaling, which is a main inflammation signaling pathway, to inhibit an inflammatory response. Therefore, the peptide can be advantageously used for alleviating or treating obesity, fatty liver, or steatohepatitis.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNzcEKgkAQxnEvHaJ6h4GuBmoEXkcbdUB3l91R8CQR2ykqsIfpcduiB-g0_OHHN8voZRq0HZbUC5fYQqk7ox0LaxV_w7JjVQOrhgsWbUcwZISPBFgjKydQoQPHtcI2wBgqbcFYGkh9RiCUWELpQoOuQBcU5sfgUGSElgey8Uc5CUo3ZFDCe7eOFpfTdfab311F24qkbHb-cZ_8_Did_c0_p95lSZYleZ6mB0z3_6k3zzBEOA</recordid><startdate>20220324</startdate><enddate>20220324</enddate><creator>ULLAH, Irfan</creator><creator>LEE, Sang-Kyung</creator><creator>LIM, Jae Yeoung</creator><creator>BAE, Su Min</creator><creator>CHUNG, Kunho</creator><scope>EVB</scope></search><sort><creationdate>20220324</creationdate><title>PHARMACEUTICAL COMPOSITION, COMPRISING INHIBITORY PEPTIDE AGAINST FAS SIGNALING, FOR PREVENTION OR TREATMENT OF OBESITY, FATTY LIVER, OR STEATOHEPATITIS</title><author>ULLAH, Irfan ; LEE, Sang-Kyung ; LIM, Jae Yeoung ; BAE, Su Min ; CHUNG, Kunho</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2022088115A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2022</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ULLAH, Irfan</creatorcontrib><creatorcontrib>LEE, Sang-Kyung</creatorcontrib><creatorcontrib>LIM, Jae Yeoung</creatorcontrib><creatorcontrib>BAE, Su Min</creatorcontrib><creatorcontrib>CHUNG, Kunho</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ULLAH, Irfan</au><au>LEE, Sang-Kyung</au><au>LIM, Jae Yeoung</au><au>BAE, Su Min</au><au>CHUNG, Kunho</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PHARMACEUTICAL COMPOSITION, COMPRISING INHIBITORY PEPTIDE AGAINST FAS SIGNALING, FOR PREVENTION OR TREATMENT OF OBESITY, FATTY LIVER, OR STEATOHEPATITIS</title><date>2022-03-24</date><risdate>2022</risdate><abstract>The present invention relates to a pharmaceutical composition comprising an inhibitory peptide against Fas signaling as an active ingredient for prevention or treatment of obesity, fatty liver, or steatohepatitis. Binding specifically to Fas, which is extensively expressed in the liver and adipose tissues in an obese state, the inhibitory peptide against Fas signaling exhibits high delivery rates to inflammatory regions caused by obesity and directly inhibits the Fas signaling, which is a main inflammation signaling pathway, to inhibit an inflammatory response. Therefore, the peptide can be advantageously used for alleviating or treating obesity, fatty liver, or steatohepatitis.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US2022088115A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title PHARMACEUTICAL COMPOSITION, COMPRISING INHIBITORY PEPTIDE AGAINST FAS SIGNALING, FOR PREVENTION OR TREATMENT OF OBESITY, FATTY LIVER, OR STEATOHEPATITIS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T07%3A06%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ULLAH,%20Irfan&rft.date=2022-03-24&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2022088115A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true